-
J Clin Oncol: Neoadjuvant Nivolumab/Ipilimumab + Adjuvant Nivolumab in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma
Time of Update: 2022-10-15
In conclusion, for patients with dMMR/MSI-H resectable gastric/gastroesophageal junction adenocarcinoma, nivolumab- and ipilimumab-based neoadjuvant therapy is feasible, with a high pathological complete response rate and no Unexpected toxicity .
-
Nature sub-journal: Scientists develop new tool for tumor fusion gene prediction
Time of Update: 2022-10-15
Recently, a research team from the University of Mainz in Germany published an article entitled "Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens" in "Nature Biotechnology", and developed a set of predicting clinical tumor sample-specific genes.
-
Detailed interpretation: Ratheke cyst
Time of Update: 2022-10-15
casePatient, female, 32 years oldChief Complaint: Dizziness, headache for more than two monthsMRI scan plus enhanced scan on admissionClinical diagnosis: MRI findings of sellar space-occupying lesionsThe sella is not large, the bottom of the sella is slightly depressed, and abnormal cystic signal shadows can be seen between the anterior and posterior pituitary lobes.
-
In the past 30 years, China's breast cancer "transcript" has been released!
Time of Update: 2022-10-15
From 1990 to 2019, the incidence, deaths, and DALYs of BC in both men and women increased significantly in China, Japan, South Korea, and worldwide .
From 1990 to 2019, the incidence, deaths, and DALYs of BC in both men and women increased significantly in China, Japan, South Korea, and worldwide .
-
Latest Technology: Multifaceted Mechanisms of Paeoniflorin in the Treatment of Tumors
Time of Update: 2022-10-15
This study reviewed the research progress of paeoniflorin's anti-tumor effect and mechanism, in order to provide new ideas and theoretical basis for the further development and clinical application of paeoniflorin .
-
MRI manifestations of gallbladder cancer (differentiated from gallbladder wall edema)
Time of Update: 2022-10-15
Another case of gallbladder carcinoma, T2WI and enhanced delayed phase showed uneven thickening of the gallbladder wall and marked enhancement .
Another case of gallbladder carcinoma, T2WI and enhanced delayed phase showed uneven thickening of the gallbladder wall and marked enhancement .
-
Imaging manifestations of hepatic pseudotumor
Time of Update: 2022-10-15
Gradual enhancement from the periphery to the center: Pathological examination showed that the lesion was rich in vascular tissue, infiltrated by a large number of inflammatory cells, and the surrounding tissue was obviously hyperemia, hemorrhage and inflammatory edema, reflecting that the lesion was in the early stage of inflammation .
-
【Nature Sub-Journal】Generate CAR-T cells within 24 hours to benefit more patients!
Time of Update: 2022-10-15
In a preclinical study, "Rapid manufacturing of non-activated potent CAR-T cells," published in Nature Biomedical Engineering, a team of researchers at the Perelman School of Medicine at the University of Pennsylvania simplified the process and used the Functional CAR-T cells with enhanced antitumor efficacy were generated in as little as 24 hours .
-
Cell sub-journal: A new strategy for tumor therapy targeting the Hippo pathway
Time of Update: 2022-10-15
SuperHippo inhibits tumorigenesis in a mouse genetic modelIn conclusion, this study not only revealed the molecular regulation mechanism of the upstream core components of the Hippo pathway, but also provided a new strategy for the development of tumor treatment programs targeting the Hippo pathway.
-
The Lancet: Smoking, drinking and obesity cause half of global cancer deaths
Time of Update: 2022-10-15
45 million cancer deaths worldwide were attributable to risk factors such as smoking, alcohol consumption and obesity, accounting for 44.
45 million cancer deaths worldwide were attributable to risk factors such as smoking, alcohol consumption and obesity, accounting for 44.
-
Lee-Fomenib syndrome with bilateral thalamic glioma in one case
Time of Update: 2022-10-14
】 Research background Li-Fraumeni syndrome (LFS) is a rare high penetrance autosomal dominant disease caused by mutations in the TP53 gene, which is easy to induce the early occurrence of a variety of malignancies, such as sarcoma, osteosarcoma, breast cancer and pheochromocytoma, etc.
-
Surgical complications of the anterior approach to epidural rock: Lariboisière experience
Time of Update: 2022-10-14
Influence of pathological and radiographic features on the occurrence of complicationsConclusion of the studyThe complication rate of EAPA is within an acceptable range, which remains a safe surgical approach that can be greatly reduced through detailed preoperative assessment, sound patient selection, and sophisticated surgical techniques.
-
Single-cell RNA sequencing reveals the evolution of the immune response in GBM progression
Time of Update: 2022-10-14
of Harvard Medical School in the United States used single-cell transcriptomics and flow cytometry to reveal large-scale comprehensive longitudinal changes in immune cell composition throughout tumor progression in a genetic mouse GBM model driven by epidermal growth factor receptors.
-
The analgesic efficacy of nonsteroidal anti-inflammatory drugs and tramadol after transnasal surgery for pituitary adenomas was compared
Time of Update: 2022-10-14
4; non-inferior P Secondary study endpoints showed that the mean VAS score for pain at 48 hours postoperative was significantly lower in the NSAIDs group than in the tramadol group (2.
-
GABPB1L loss significantly increased the chemotherapy effect of TERTp-mutant GBM
Time of Update: 2022-10-13
reported the effect of GABPB1L on the growth of TERTpMut GBM and the effect of temozolomide chemotherapy; The article was published online in the March 2021 issue of PNAS.
-
The second-line treatment of liver cancer has added "fierce general"! The successful approval of the indication for remoxizumab has brought more hope to patients in China
Time of Update: 2022-10-13
The results showed that the study reached the main positive endpoint of OS, and the survival benefit of patients with advanced liver cancer with advanced liver cancer with remoxizumab single-agent second-line treatment AFP≥ 400 ng/ml was significantly higher than placebo 。 Among them, the median OS of patients in the remoxilizumab group was 8.
-
Pioneers in the field of KRAS co-founded! The new venture received $125 million to help develop precision anti-cancer therapies
Time of Update: 2022-10-13
▲If you have any business needs, please long press to scan the QR code above, or▎Editor of WuXi AppTec content teamNested Therapeutics today announced the completion of a $90 million Series A funding round, which will advance Nested's total funding to $125 million to help develop its next generation of precision medicine drugs for cancer.
-
The world's first clinical study of small cell lung cancer immunotherapy listed in the international top journal JAMA, H drug Hans-like combination chemotherapy first-line ® treatment of extensive small cell lung cancer positive results were released
Time of Update: 2022-10-13
On September 27, 2022, the international multicenter research led by Professor Cheng Ying, ASTRUM-005 research, one of the world's top four medical journals, Journal of the American Medical Associatio
-
Clinically necessary PD-1/PD-L1 immune checkpoint inhibitors are recognized for safety in the clinical application of urogenital tumors
Time of Update: 2022-10-13
IntroductionIn the field of urogenital tumors, several clinical trials have confirmed the excellent clinical efficacy of immune checkpoint inhibitors (ICIs) in urothelial carcinoma (UC), renal cell ca
-
2022CSH Prof. Mingfeng Zhao: Research progress of CAR-T cells in the treatment of acute myeloid leukemia
Time of Update: 2022-10-13
The 2018 American Hematology Annual Meeting (ASH) reported efficacy results in a targeted CD123 CAR-T therapy in which 4/6 patients with AML achieved complete remission (CR) after treatment; However, many researchers, including Professor Zhao Mingfeng's team, have not been able to repeat such good results in subsequent trials.
